RT Journal Article
SR Electronic
T1 Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.31.21250872
DO 10.1101/2021.01.31.21250872
A1 Junjiang Li
A1 Philippe J. Giabbanelli
YR 2021
UL http://medrxiv.org/content/early/2021/02/03/2021.01.31.21250872.abstract
AB Background In 2020, COVID-19 has claimed more than 300,000 deaths in the US alone. While non-pharmaceutical interventions were implemented by federal and state governments in the USA, these efforts have failed to contain the virus. Following the FDA approval of two COVID-19 vaccines, however, the hope for the return to normalcy is renewed. This hope rests on an unprecedented nation-wide vaccine campaign, which faces many logistical challenges and is also contingent on several factors whose values are currently unknown.Objective We study the effectiveness of a nation-wide vaccine campaign in response to different vaccine efficacies, the willingness of the population to be vaccinated, and the daily vaccine capacity under two different federal plans. To characterize the possible outcomes most accurately, we also account for the interactions between non-pharmaceutical interventions and vaccines, through six scenarios that capture a range of possible impact from non-pharmaceutical interventions.Methods We use large-scale cloud-based agent-based simulations by implementing the vaccination campaign using Covasim, an open-source ABM for COVID-19 that has been used in several peer-reviewed studies and accounts for individual heterogeneity as well as a multiplicity of contact networks. Several modifications to the parameters and simulation logic were made to better align the model with current evidence. We chose six non-pharmaceutical intervention scenarios and applied the vaccination intervention following both the plan proposed by Operation Warp Speed (former Trump administration) and the plan of one million vaccines per day, proposed by the Biden administration. We accounted for unknowns in vaccine efficacies and levels of population compliance by varying both parameters. For each experiment, the cumulative infection growth is fitted to a logistic growth model, and the carrying capacities and the growth rates are recorded.Results For both vaccination plans and all non-pharmaceutical intervention scenarios, the presence of the vaccine intervention considerably lowers the total number of infections when life returns to normal, even when the population compliance to vaccines is as low at 20%. We noted an unintended consequence: given the vaccine availability estimates under both federal plans and the focus on vaccinating individuals by age categories, a significant reduction in non-pharmaceutical interventions results in a counterintuitive situation in which higher vaccine compliance then leads to more total infections.Conclusions Although potent, vaccines alone cannot effectively end the pandemic given the current availability estimates and the adopted vaccination strategy. Non-pharmaceutical interventions need to continue and be enforced to ensure high compliance, so that the rate of immunity established by vaccination outpaces that induced by infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors thank the Microsoft AI for Health program for supporting this research effort through a philanthropic grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study uses secondary data and models, hence it is exempt from IRB or ethics committee approvals.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study uses secondary data and models which have been publicly released.ABMAn Agent-Based Model is a computational model that simulates how individuals (i.e., ‘agents’) change through interactions with others and their environment.CDCThe Centers for Disease Control and Prevention is a national public health institute in the United States.COVID-19Disease caused in humans by a new strain of the severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 (initially named 2019-nCoV).VOC-202012/01Variant of Concern 2020/12/01 is a new strain, first identified in the UK and currently spreading in the USA, whose unusually large number of changes in genomes result in higher transmissibility.